A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
NCT04136873
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
130
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
CVL-231
DRUG:
Matching Placebo
Sponsor
Cerevel Therapeutics, LLC